Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli.
The biotech, which is seeking to challenge Regeneron and Roche, unveiled this week new corporate branding and a made-over website. Ocular has retained its name but changed its logo. Previously, the logo was dominated by an angled, double-height “O” at the start of the company’s name. Now, Ocular has created a new logo that it says emphasizes its focus on retinal diseases.
“Designed with visual accessibility at its core, the logo is science-based, transformative and joyful,” according to the company's announcement. “The circular ‘O’ represents the eye and the retina, while the full-spectrum color palette captures the vibrancy of human vision and the richness of life it enables. The treatment of the ‘X’ represents the intersection of where the company has been and where it is going.”
The company also published an “anthem video” as part of the rebrand. The 75-second film uses point-of-view shots to convey the experience of developing a retinal disease. The faces of loved ones become obscured by darkening spots that mimic vision loss, as a voiceover says, “We understand the experience of retinal disease, its impact on patients losing their sight.”
The video also introduces the tagline, “Our retina experience will redefine your retina experience.”
Ocular has redesigned its website around the new branding and rolled out the logo across social media. The changes give the drugmaker a new look ahead of the anticipated publication of top-line phase 3 data on Axpaxli in wet age-related macular degeneration (AMD) in the first quarter of 2026.
Ocular is aiming to improve outcomes in conditions including wet AMD by reducing the frequency of dosing. The biotech’s late-phase program is aiming to show that Axpaxli can be given every six or 12 months; patients currently can go up to four months between doses of Roche’s Vabysmo.